These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 29471865)

  • 1. A multicentre, randomised, non-inferiority clinical trial comparing a nifurtimox-eflornithine combination to standard eflornithine monotherapy for late stage Trypanosoma brucei gambiense human African trypanosomiasis in Uganda.
    Kansiime F; Adibaku S; Wamboga C; Idi F; Kato CD; Yamuah L; Vaillant M; Kioy D; Olliaro P; Matovu E
    Parasit Vectors; 2018 Feb; 11(1):105. PubMed ID: 29471865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial.
    Priotto G; Kasparian S; Mutombo W; Ngouama D; Ghorashian S; Arnold U; Ghabri S; Baudin E; Buard V; Kazadi-Kyanza S; Ilunga M; Mutangala W; Pohlig G; Schmid C; Karunakara U; Torreele E; Kande V
    Lancet; 2009 Jul; 374(9683):56-64. PubMed ID: 19559476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-hospital safety in field conditions of nifurtimox eflornithine combination therapy (NECT) for T. b. gambiense sleeping sickness.
    Schmid C; Kuemmerle A; Blum J; Ghabri S; Kande V; Mutombo W; Ilunga M; Lumpungu I; Mutanda S; Nganzobo P; Tete D; Mubwa N; Kisala M; Blesson S; Mordt OV
    PLoS Negl Trop Dis; 2012; 6(11):e1920. PubMed ID: 23209861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of Nifurtimox Eflornithine Combination Therapy (NECT) in T. b. gambiense second stage sleeping sickness patients in the Democratic Republic of Congo: Report from a field study.
    Kuemmerle A; Schmid C; Bernhard S; Kande V; Mutombo W; Ilunga M; Lumpungu I; Mutanda S; Nganzobo P; Tete DN; Kisala M; Burri C; Blesson S; Valverde Mordt O
    PLoS Negl Trop Dis; 2021 Nov; 15(11):e0009903. PubMed ID: 34748572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial.
    Mesu VKBK; Kalonji WM; Bardonneau C; Mordt OV; Blesson S; Simon F; Delhomme S; Bernhard S; Kuziena W; Lubaki JF; Vuvu SL; Ngima PN; Mbembo HM; Ilunga M; Bonama AK; Heradi JA; Solomo JLL; Mandula G; Badibabi LK; Dama FR; Lukula PK; Tete DN; Lumbala C; Scherrer B; Strub-Wourgaft N; Tarral A
    Lancet; 2018 Jan; 391(10116):144-154. PubMed ID: 29113731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2/3 trial.
    Betu Kumeso VK; Kalonji WM; Rembry S; Valverde Mordt O; Ngolo Tete D; Prêtre A; Delhomme S; Ilunga Wa Kyhi M; Camara M; Catusse J; Schneitter S; Nusbaumer M; Mwamba Miaka E; Mahenzi Mbembo H; Makaya Mayawula J; Layba Camara M; Akwaso Massa F; Kaninda Badibabi L; Kasongo Bonama A; Kavunga Lukula P; Mutanda Kalonji S; Mariero Philemon P; Mokilifi Nganyonyi R; Embana Mankiara H; Asuka Akongo Nguba A; Kobo Muanza V; Mulenge Nasandhel E; Fifi Nzeza Bambuwu A; Scherrer B; Strub-Wourgaft N; Tarral A
    Lancet Infect Dis; 2023 Apr; 23(4):463-470. PubMed ID: 36460027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo.
    Priotto G; Kasparian S; Ngouama D; Ghorashian S; Arnold U; Ghabri S; Karunakara U
    Clin Infect Dis; 2007 Dec; 45(11):1435-42. PubMed ID: 17990225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prescription of concomitant medications in patients treated with Nifurtimox Eflornithine Combination Therapy (NECT) for T.b. gambiense second stage sleeping sickness in the Democratic Republic of the Congo.
    Kuemmerle A; Schmid C; Kande V; Mutombo W; Ilunga M; Lumpungu I; Mutanda S; Nganzobo P; Ngolo D; Kisala M; Valverde Mordt O
    PLoS Negl Trop Dis; 2020 Jan; 14(1):e0008028. PubMed ID: 31986140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: Médecins Sans Frontières experience in the Democratic Republic of the Congo.
    Alirol E; Schrumpf D; Amici Heradi J; Riedel A; de Patoul C; Quere M; Chappuis F
    Clin Infect Dis; 2013 Jan; 56(2):195-203. PubMed ID: 23074318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mortality trends and risk factors in advanced stage-2 Human African Trypanosomiasis: A critical appraisal of 23 years of experience in the Democratic Republic of Congo.
    Kazumba LM; Kaka JT; Ngoyi DM; Tshala-Katumbay D
    PLoS Negl Trop Dis; 2018 Jun; 12(6):e0006504. PubMed ID: 29897919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nifurtimox plus Eflornithine for late-stage sleeping sickness in Uganda: a case series.
    Checchi F; Piola P; Ayikoru H; Thomas F; Legros D; Priotto G
    PLoS Negl Trop Dis; 2007 Nov; 1(2):e64. PubMed ID: 18060083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-course eflornithine in Gambian trypanosomiasis: a multicentre randomized controlled trial.
    Pépin J; Khonde N; Maiso F; Doua F; Jaffar S; Ngampo S; Mpia B; Mbulamberi D; Kuzoe F
    Bull World Health Organ; 2000; 78(11):1284-95. PubMed ID: 11143188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacodynamic Modeling of Eflornithine-Based Treatments Against Late-Stage Gambiense Human African Trypanosomiasis and Efficacy Predictions of L-eflornithine-Based Therapy.
    Amilon C; Boberg M; Tarning J; Äbelö A; Ashton M; Jansson-Löfmark R
    AAPS J; 2022 Mar; 24(3):48. PubMed ID: 35338410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy for second-stage human African trypanosomiasis.
    Lutje V; Seixas J; Kennedy A
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD006201. PubMed ID: 23807762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NECT is next: implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sickness.
    Yun O; Priotto G; Tong J; Flevaud L; Chappuis F
    PLoS Negl Trop Dis; 2010 May; 4(5):e720. PubMed ID: 20520803
    [No Abstract]   [Full Text] [Related]  

  • 16. Chemotherapy for second-stage Human African trypanosomiasis.
    Lutje V; Seixas J; Kennedy A
    Cochrane Database Syst Rev; 2010 Aug; (8):CD006201. PubMed ID: 20687080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy for second-stage human African trypanosomiasis: drugs in use.
    Lutje V; Probyn K; Seixas J; Bergman H; Villanueva G
    Cochrane Database Syst Rev; 2021 Dec; 12(12):CD015374. PubMed ID: 34882307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study.
    Kande Betu Ku Mesu V; Mutombo Kalonji W; Bardonneau C; Valverde Mordt O; Ngolo Tete D; Blesson S; Simon F; Delhomme S; Bernhard S; Mahenzi Mbembo H; Mpia Moke C; Lumeya Vuvu S; Mudji E'kitiak J; Akwaso Masa F; Mukendi Ilunga M; Mpoyi Muamba Nzambi D; Mayala Malu T; Kapongo Tshilumbwa S; Botalema Bolengi F; Nkieri Matsho M; Lumbala C; Scherrer B; Strub-Wourgaft N; Tarral A
    Lancet Glob Health; 2021 Jul; 9(7):e999-e1008. PubMed ID: 34143998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Toxicity of Fexinidazole and Nifurtimox Plus Eflornithine in the Treatment of African Trypanosomiasis: A Systematic Review.
    Hidalgo J; Ortiz JF; Fabara SP; Eissa-Garcés A; Reddy D; Collins KD; Tirupathi R
    Cureus; 2021 Aug; 13(8):e16881. PubMed ID: 34513456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of human African trypanosomiasis--present situation and needs for research and development.
    Legros D; Ollivier G; Gastellu-Etchegorry M; Paquet C; Burri C; Jannin J; Büscher P
    Lancet Infect Dis; 2002 Jul; 2(7):437-40. PubMed ID: 12127356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.